Amgen Announces Data Being Presented At ASH 2019

Results From Phase 3 CANDOR Study Evaluating KYPROLIS® (Carfilzomib) in Combination With DARZALEX® (Daratumumab) in Relapsed or Refractory Multiple Myeloma Patients Accepted as Late-Breaking Abstract New Data From the Children’s Oncology Group Phase 3 Trial (AALL1331) of BLINCYTO® (Blinatumomab)

Original Source